A US drug development company based at Queen’s University Belfast is investing £8 million to test it cancer treatment in human trials.
CV6 Therapeutics will put its first oncology drug, which works alongside standard cancer therapies to induce cancer cell DNA damage and cell death, through phase 1a clinical trials and will also perform further development work. It will focus on safety, measuring how the drug is absorbed by the body, identifying optimal dosing levels and gathering initial indications of anti-cancer activity.
The company has raised over £5 million in financing from a syndicate of investors. The investment round included funding from Invest NI, QUBIS (the commercialisation arm at Queens University), CoFund NI, managed by Clarendon Fund Managers and Techstart Ventures as well as US-based and local investors. It has also received an R&D grant from Invest Northern Ireland valued over £3m to support the Phase 1a trial.
